Clinical Trial Update: Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for topical KB105 in Autosomal Recessive Ichthyosis (ARCI).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Ichthyosis

Drugs mentioned

• KB105

Snippet

Sponsor: Krystal Biotech, Inc. | Conditions: Autosomal Recessive Ichthyosis | Phase 2 | Status: UNKNOWN